Effect of tapentadol for the cancer pain

Effect of tapentadol for the cancer pain - tapentadol for the cancer pain

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016414

Enrollment

Registered

2015-02-02

Start date

2015-02-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer patients

Interventions

tapentadol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: cancer patients with cancer related pain with four or more NRS score of pain

Exclusion criteria

Exclusion criteria: 1) bad controlled liver, kidney, heart, lung , hypertension and infectious diseases 2) psychiatric diseases including depression 3) pregnancy or breast-feeding 4) intake of SNRI inhibitor 5) the cases whom the doctor decide not to be the indication

Design outcomes

Primary

Measure	Time frame
Comparison of pain NRS scores between neuropathic pain and nociceptive pain	—

Secondary

Measure	Time frame
Comparison of tapentadol doses between neuropathic pain or nociceptive pain	—

Countries

Japan

Contacts

Public ContactYasuo Hirayama

Higashi Sapporo Hospital Department of Hematology Oncology

hirayama@hsh.or.jp011-812-2311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026